Management of patients with extensive facial skin cancers is a challenge. We present a series of nine patients with extensive facial skin cancers and our experience with managing these patients.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.cps.2004.11.010 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
A phase 2 basket study of talabostat, a small-molecule inhibitor of dipeptidyl peptidases, administered in combination with pembrolizumab in patients with advanced solid cancers.
Cancer
February 2025
Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Background: Talabostat, an oral small molecule inhibitor of dipeptidyl peptidases (DPP4 and DPP8/9), has shown synergistic activity with immune checkpoint inhibitors in preclinical studies. This open label, phase 2 basket trial assessed the antitumor activity of combining talabostat and pembrolizumab (anti-programmed death-1 antibody) in advanced solid tumor patients.
Methods: The primary objective was assessment of dose-limiting toxicity (DLT) rates in the first six patients (lead-in stage) and response rate (efficacy stage; included cohort A [checkpoint inhibitor (ICI) naive] and cohort B [ICI pretreated]) for the study treatment using the Response Evaluation Criteria in Solid Tumors (RECIST) v1.
The timing and safety of topical timolol treatment for superficial infantile hemangioma: a retrospective cohort study.
Eur J Pediatr
January 2025
Department of Pediatric Surgery, Sichuan Provincial People's Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China.
Unlabelled: Numerous studies have shown that topical timolol is effective in treating infantile hemangioma (IH) with minimal adverse events. However, consensus is lacking on optimal timing, dosage, frequency, and safety parameters for this treatment. This study aims to explore the timing and safety of topical timolol treatment for superficial IH.
View Article and Find Full Text PDFThe impact of imprecise case definitions in electronic health record research: a melanoma case-study from the Million Veteran Program.
Arch Dermatol Res
January 2025
VA Boston Healthcare System, Boston, MA, USA.
Cases for a disease can be defined broadly using diagnostic codes, or narrowly using gold-standard confirmation that often is not available in large administrative datasets. These different definitions can have significant impacts on the results and conclusions of studies. We conducted this study to assess how using melanoma phecodes versus histologic confirmation for invasive or in situ melanoma impacts the results of a genome-wide association study (GWAS) using the Million Veteran Program.
View Article and Find Full Text PDFMandibular hybrid odontogenic tumor.
Oral Maxillofac Surg
January 2025
Department of Dentistry, State University of Maringá (UEM), Maringá, Brazil.
Background: Hybrid Odontogenic Tumors (HOT) are defined by the presence of two or more independent odontogenic tumors that originate from and affect the same maxillofacial site.
Methods: The present study is the first case report of a mandibular HOT consisting of Ameloblastoma, Calcifying Epithelial Odontogenic Tumor, and Ameloblastic Fibroma.
Case Report: A 37-year-old otherwise healthy male presented with the chief complaint of swelling in the right mandibular body.
Efficacy of the 595 nm pulsed dye laser in the treatment of hemangiomas in Vietnamese patients.
Lasers Med Sci
January 2025
Aalborg University Hospital, Aalborg, Denmark.
Hemangiomas are common benign vascular tumors that often present in childhood. The 595 nm pulsed dye laser (PDL) is now being widely used to treat vascular skin lesions. This case series was performed to review the therapeutic efficacy and safety of PDL in the treatment of hemangiomas among Vietnamese patients.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!